Motif Bio Share Discussion Threads

[davidpines] 14/2/2019 09:09

Mr wooden top so you bought a few at 5p and now you think won't go lower in the next few daysIs that because you have bought so the price won't fallTomorrow this will be closer to 2p

[pyglet] 14/2/2019 09:08

It looks like they have been flogging a dead horse from the outset. If the the FDA said that this should not be developed further then it would seem as if MTFB has gone against the will of the FDA and that in no way are they ever going to change their mind.

[mr woodentop] 14/2/2019 09:07

bought a few at 5p - figure unlikely to go lower for the next few days at least

[tomboyb] 14/2/2019 09:02

Have acquired a few -

30-45 days so not going bust yet -

[kirk 6] 14/2/2019 09:02

Here we go chaps 10p easy on the bounce I bought 900k shares at around 5p on various clips

[timbo003] 14/2/2019 08:57

The potential for questions on potential heptatoxicity were presumably well covered in the NDA submission, as they came up in the original application back in 2009.

Surely they would have discussed these with FDA at the pre NDA meeting and agreed what needed to be done in order to address the questions. They must have been satisfied that they had covered this in the current NDA, otherwise they would have not have gone ahead with the submission?

Extract from EMEA response 2009

[pre] 14/2/2019 08:57

so FDA asked for more information...they haven't rejected it on that basis...is that correct?

[bountyhunter] 14/2/2019 08:55

lionheart69uk1 - 13 Feb 2019 - 22:15:38 - 2752 of 2824
No idea why you are all getting so excited. The market has already factored the probability of success into the current share prices. I am not expecting any sudden movement unless a FDA rejection occurs, which I sincerely doubt.

[lionheart69uk1] 14/2/2019 08:47

Thank goodness I wasn't tempted by all the silly optimism on here.

[encarter] 14/2/2019 08:45

Iclaprim is an optimized analog of trimethoprim that was discovered by scientists at Roche.[5] Arpida was spun out of Roche in 1998[5][6] and acquired iclaprim from Roche in 2001.[7]:77 Arpida held an IPO on the Swiss stock exchange in 2005.[8]Arpida ran two Phase III clinical trials for complicated skin and skin structure infections, called ASSIST 1 and 2, that were completed by 2008 but as of 2017 had not been published in the medical literature.[2] A new drug application was filed with the FDA bssed on these trials and was rejected due to failure to show non-inferiority and due to safety concerns, especially drug-induced QT prolongation.[2][9] The FDA advisory committee said that the drug "should not be developed further" based on the results presented.[10] A parallel application for marketing approval to the EMA was withdrawn in 2009; in the announcement of the withdrawal, the EMA said that there was insufficient data from clinical studies to justify the dosage proposed by the company and that resistance to the drug had already been seen in the clinical trial data.[11]Arpida collapsed after the rejection by the FDA and the EMA withdrawal.[6] Arpida and the privately owned Swiss company Evolva began discussing an acquisition of Arpida by Evolva, which would allow Evolva to go public via a reverse merger in September 2009.[12]Arpida sold off iclaprim to Acino Pharma in November 2009,[13] and in December 2009 Arpida and Evolva completed their transaction.[14]Acino sold the rights to iclaprim, its data and regulatory filings, and manufactured drug to a group called Life Sciences Management Group, Inc. of Bethesda, Maryland, in September 2013 and that company assigned its rights to a company called Nuprim,[7]:F-32which had been formed by the former CEO, CSO, and US agent of Arpida in 2014.[15] In December 2014 Motif BioSciences Inc. and Nuprim signed an agreement allowing Motif to acquire the iclaprim assets, and the transaction was completed in April 2015.[7]:iv

[imjustdandy] 14/2/2019 08:36

Some pharma co will scoop this up for 10p

[kirk 6] 14/2/2019 08:35

Looks to be massively overdone now

[imjustdandy] 14/2/2019 08:34

200m shares will be churned today. Def worth a punt at 5

[telbap] 14/2/2019 08:32

Tried several times to buy. HL giving me no quote.Left a fill or kill on open price...gulp!500£. Worth the punt I think

[pyglet] 14/2/2019 08:29

Certainly not worth selling at the moment. Annoying that it's going to take 45 days to even talk to the FDA

[bocase] 14/2/2019 08:27

Plenty willing to buy at this price. 900 000 on the bid at 4.9p

For long term holders, as bounty says, could still be a blockbuster. Just a different time perspective required.

Right off now to take it out on a golf ball.

[mike1608] 14/2/2019 08:26

was funny how people think they bought cheap at the 37p drop, my stop loss kicked in. was annoyed but not anymore

[spmc] 14/2/2019 08:26

Got my average down to 12p hopefully we will bounce to that so I can get my money back, should just be a case of providing more data this has done 4 phase 3 trials now so the data will be there.

[pre] 14/2/2019 08:26

10p today,,,,let's see

[encarter] 14/2/2019 08:22

Placees will want a discount to wherever the share price settles and it might prove difficult to raise any cash now.

[bountyhunter] 14/2/2019 08:20

Yes I agree bocase, now it's back to weather/ship watching!

[bocase] 14/2/2019 08:17

Yes one to tuck away and forget now.

The placing will already be priced in I would think so can only see a slow recovery from here.

An alternative to a placing would be an acquisition by a larger pharma. That may provide a bit of a premium.

[mike1608] 14/2/2019 08:16

sold 120k 2 days ago, so lucky